Skip to content Skip to footer

Innovation Meets Impact: Jaime Leija on BioLab’s Patient-First Approach

Shots:  BioLab balances innovation with real-world impact through a dual strategy that combines rapid commercialization of FDA-approved or near-market solutions like Imbed with continued investment in long-term innovations such as cureVision and terraplasma, ensuring both immediate clinical needs and future breakthroughs in wound care are effectively addressed.    BioLab’s growth is driven by sharp strategic discipline, focusing on chronic outpatient…

Read more

Key Biosimilars Events of October 2025  

Shots:        Biosimilars are developed to match approved biologic therapies in safety, and efficacy, ensuring comparable clinical outcomes. They represent a critical pathway to reducing healthcare costs by providing affordable alternatives to expensive branded biologics, delivering meaningful savings for both patients and payers  In a key development, Celltrion’s Eydenzelt (Biosimilar, Eylea) Receives the US FDA’s Approval…

Read more

Viewpoints_Manojkumar Bupathy

Advancing Cancer Therapy Delivery: Manojkumar Bupathy from Rocky Mountain Cancer Centers in Conversation with PharmaShots

Shots:  Addressing a high unmet medical need, PharmaShots had a riveting dialogue exchange with Manojkumar Bupathy from Rocky Mountain Cancer Centers  Manojkumar shared insights from the real-world study that analysed the treatment pattern and clinical outcomes in patients with locally advanced/metastatic urothelial carcinoma   The study reveals that four out of the ten patients received only…

Read more